Clinical Trial Update: Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PLX3397 for safety and efficacy in adults with relapsed or refractory Hodgkin Lymphoma has completed; results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• PLX3397 (PLX3397)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2013-03-15